Celecoxib

Licensed by Pfizer Catalog No.S1261 Synonyms: SC 58635

Celecoxib Chemical Structure

Molecular Weight(MW): 381.37

Celecoxib is a selective COX-2 inhibitor with IC50 of 40 nM in Sf9 cells.

Size Price Stock Quantity  
USD 97 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 23 Publications

Purity & Quality Control

Choose Selective COX Inhibitors

Biological Activity

Description Celecoxib is a selective COX-2 inhibitor with IC50 of 40 nM in Sf9 cells.
Targets
COX-2 [1]
(Sf9 cells)
40 nM
In vitro

Celecoxib shows low sensitivity against COX-1 with IC50 of 15 μM. [1] Celecoxib shows an anti-proliferative effect on nasopharyngeal carcinoma (NPC) cell lines including HNE1 and CNE1-LMP1 with IC50 of 32.86 μM and 61.31 μM, respectively. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
A549 NHPkPIFHfW6ldHnvckBCe3OjeR?= MnzNNE4yNTNyIN88US=> NFHBS2U1QCCq M374Rolv\HWlZYOgTWNCVS1zIHX4dJJme3Orb36gc44h[m:2aDDwdo91\WmwIHHu[EBuWk6DIHzleoVt M1u5eFI3PTF|MUey
H460 NV\hOo5ETnWwY4Tpc44hSXO|YYm= MV:wMlEuOzBizszN MVK0PEBp MWjpcoR2[2W|IFnDRW0uOSCneIDy[ZN{cW:wIH;uJIJwfGhicILveIVqdiCjbnSgcXJPSSCuZY\lcC=> M2SxfFI3PTF|MUey
HKESC-2 NVPtTWhXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXrKfYFtOjEEoN88US=> NHfXeFg1QMLiaNMg M3qxUpNq\26rZnnjZY51dHliaX7jdoVie2W|IITo[UBKSzVywrD2ZYx2\XNib3[gc5hidGmybHH0bY7DqA>? MnjPNlY1PzR4OUO=
CaES-17 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWjUeo5wOjEEoN88US=> M{f2[FQ5yqCqwrC= NV3jcYp6e2mpbnnmbYNidnSueTDpcoNz\WG|ZYOgeIhmKEmFNUFCpJZidHWnczDv[kBwgGGuaYDsZZRqdsLi M{PsUVI3PDd2Nkmz
HKESC-2 Mki5RZBweHSxc3nzJGF{e2G7 M1e4TlIxyqEQvF2= MXq0POKhcMLi NIr3NYVz\WS3Y3XzJI95[WyrcHzheIlvNWmwZIXj[YQh[XCxcITvd4l{ NE\zUogzPjR5NE[5Ny=>
CaES-17 NW\hTVRjSXCxcITvd4l{KEG|c3H5 M{LGclIxyqEQvF2= NVq4fZJoPDkEoHlCpC=> MX;y[YR2[2W|IH;4ZYxqeGyjdHnuMYlv\HWlZXSgZZBweHSxc3nz M3vtTlI3PDd2Nkmz
A549 M3;U[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3jGfVUuOTZyIN88US=> NH[xZ3Y1QMLiaNMg MnXzSG1UVw>? MYnJR|UxRTF4Mz60JO69VQ>? M1LGPFI3PDZ2NkSz
HCC827 MnrGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml\pOU0yPjBizszN MVW0POKhcMLi M4OzU2ROW09? M{HUWGlEPTB;NkmuNkDPxE1? NGH6[YIzPjR4NE[0Ny=>
A549 NXvqN5dJSXCxcITvd4l{KEG|c3H5 MVS4NEDDvU1? MkmxOFjDqGkEoB?= MWrEUXNQ NETweIpqdmS3Y3XzJIFxd3C2b4Ppdy=> MVKyOlQ3PDZ2Mx?=
HCC827 M{LPd2Fxd3C2b4Ppd{BCe3OjeR?= MnPIPFAhyrWP NXH0O|BZPDkEoHlCpC=> M{HXcGROW09? MUfpcoR2[2W|IHHwc5B1d3Orcx?= MlfmNlY1PjR4NEO=
SGC-7901/DDP MkDiSpVv[3Srb36gRZN{[Xl? MoroNVDDqML3TR?= NUO2NGQ{OjRiaB?= NUPUXFY4cW6qaXLpeJMh[3mlbH;vfJlo\W6jc3WtNkBidmRiUD3ncJlkd3C{b4TlbY4h\XiycnXzd4lwdg>? M1nHbFI3PDB5NkWz
SGC-7901  NF;pWm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3P0[|I1yqCqwrC= NEDGUGNKSzVyPUGxOU4xQCEQvF2= NEfHc3UzPjRyN{[1Ny=>
SGC-7901/DDP NHXJZ|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHTJNWszPMLiaNMg MUHJR|UxRTN3LkS1JO69VQ>? NX;1foo6OjZ2MEe2OVM>
SGC-7901/DDP NFi1dnpCeG:ydH;zbZMhSXO|YYm= NE\tblEyOMLiwsXN MWeyOEBp Mln1bY5lfWOnczDhdI9xfG:|aYOgZ49u[mmwZXSge4l1cCC5aYToJINqe3CuYYTpci=> Mlq5NlY1ODd4NUO=
SGC-7901/DDP MVrGeY5kfGmxbjDBd5NigQ>? NX;4fllbOTEEoNM1US=> NEXwVWIzPCCq NHPLTlZqdmirYnn0d{B1cGViZYjwdoV{e2mxbjDv[kBRNWeueXPvdJJwfGWrbjD0bJJwfWeqIHLsc4NscW6pIFXQNkwh[W6mIHnuZYN1cX[jdHnu[{BRU0FiYX7kJGNTTUMEoB?= Mn\uNlY1ODd4NUO=
SGC-7901/DDP NYDSflJ2TnWwY4Tpc44hSXO|YYm= Mo[0NVDDqML3TR?= M3PjVlI1KGh? NHHWNJNk[XW|ZYOgZUBu[XKtZXSg[IVkemWjc3WgbY4hfGinIHzleoVtKG:oIFLjcE0zKHC{b4TlbY4> MWCyOlQxPzZ3Mx?=
H357 NGLzenVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV2yZ2cyPy53L{GwJO69VQ>? NEizb4g1QCCq NGfGZWxFVVOR NGrZT|ZqdmirYnn0d{Bk\WyuIHfyc5d1cMLiY3;tZolv\WRid3n0bEBU[WK3dH;jcIF5 NHHjdogzPjByOUi3OC=>
TAF NUnEO4pHTnWwY4Tpc44hSXO|YYm= MorUNVDDqML3TR?= NW\TXVF5PyCm MlHhZYZn\WO2czDURWZ{KGGmaHXzbZZmKHC{b4DldpRq\XN? NWXTO3U5OjV7OEexNlc>
TAF MkDoSpVv[3Srb36gRZN{[Xl? MnnqNVDDqML3TR?= Mnj1N|AuOTJyIH3pci=> MmnGdI9wemy7IHHm[oVkfHNiZFHreEBxcG:|cHjvdplt[XSrb36gZ49ve2WzdXXueEB1dyCHR1[gd4lodmGuaX7n NUjsNYVCOjV7OEexNlc>
TAF MnTtSpVv[3Srb36gRZN{[Xl? NWn3eJY3OTEEoNM1US=> M4HCbVQ5KGh? NEPwbZVqdmO{ZXHz[ZMhTUeIUjDtVm5CKGGwZDDwdo91\WmwIHX4dJJme3Orb36= MXGyOVk5PzF{Nx?=
PANC-1 NVTsVmNMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHvkNYgzOC94MD:xNFAh|ryP NVLhcpp6OjRxNEivO|IhcA>? NFG3ZWpqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDic5RpKHSrbXWgZY5lKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= NYXwfldEOjV7N{OwOlI>
PANC-1 NU\3eGRWTnWwY4Tpc44hSXO|YYm= M2rwXFIxNzZyL{GwNEDPxE1? MXSyOEBp MY\heJRmdnWjdIOgZ4VtdCCrbo\hd4lwdiCjbnSgcYloemG2aX;uJIlvKGFiY3;uZ4VvfHKjdHnvck1l\XCnbnTlcpQhdWGwbnXyxsA> MWCyOVk4OzB4Mh?=
HeLa  NEPmVlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1zqSVIxyqEQvF5CpC=> NGrWN2szPMLiaB?= MWDlcohidmOnczDyZYRq[XSrb36tbY5lfWOnZDDpcohq[mm2aX;uJI9nKGOnbHygdJJwdGmoZYLheIlwdg>? M1HVXVI2PzdyNEKz
SACC-83 M17Xe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{fJWlIxyqEQvF5CpC=> M4rnbVI1yqCq NYTuelNn\W6qYX7j[ZMhemGmaXH0bY9vNWmwZIXj[YQhcW6qaXLpeIlwdiCxZjDj[YxtKHC{b3zp[oVz[XSrb36= MmjMNlU4PzB2MkO=
HeLa  NF3mSXJCeG:ydH;zbZMhSXO|YYm= NGS1cmEzOMLizszNxsA> M1vMWVI1yqCq NGnBS49mdmijbnPld{Bz[WSrYYTpc44ucW6mdXPl[EBqdmirYnn0bY9vKG:oIHPlcIwh[XCxcITvd4l{ NV34WWVNOjV5N{C0NlM>
SACC-83 NV3JNpBXSXCxcITvd4l{KEG|c3H5 NVK2NIRjOjEEoN88UeKh MlnGNlTDqGh? MmDv[Y5p[W6lZYOgdoFlcWG2aX;uMYlv\HWlZXSgbY5pcWKrdHnvckBw\iClZXzsJIFxd3C2b4Ppdy=> MYqyOVc4ODR{Mx?=
HeLa  NH7KclFHfW6ldHnvckBCe3OjeR?= NGnTeogzOC92MD:4NEDPxE1? NEDi[G4zPMLiaB?= NVviV|Y1fXC{ZXf1cIF1eyCSVFXOJJBienSrYXzsfUBjgSCrbnjpZol1cW6pIGPwNUwh[W6mIHHjeIl3[XSnczDQWGVPKGGwZDDpcoFkfGm4YYTld{BCU1R? NUn5dGFDOjV5N{C0NlM>
SACC-83 NWOybVI4TnWwY4Tpc44hSXO|YYm= MlrFNlAwPDBxOECg{txO NGHmUnIzPMLiaB?= MVL1dJJm\3WuYYTzJHBVTU5icHHyeIlidGy7IHL5JIlvcGmkaYTpcochW3BzLDDhcoQh[WO2aY\heIV{KFCWRV6gZY5lKGmwYXP0bZZifGW|IFHLWC=> NFnJTW0zPTd5MESyNy=>
HLCZ01 NEXvbnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHrCS|cx6oDVNkFCpOK2VQ>? NYjoPItNPDhiaB?= MV7EUXNQ MWTpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=> NXjmd5A{OjV5MkS4PVk>
HLCZ01 NFLZd2hHfW6ldHnvckBCe3OjeR?= NW[0SYlpPDEEoN88US=> NIq3fmQzPCCq MkLDSG1UVw>? NV;2cZJ7cW6lcnXhd4V{KGGlY4XteYxifGmxbjDv[kBIOC:JMT3wbIF{\SClZXzsd{Bkd22kaX7l[EB4cXSqIFnGUk3PuQ>? NF74bYczPTd{NEi5PS=>
HLCZ01 NFr1[nBCeG:ydH;zbZMhSXO|YYm= MWW0NOKh|ryP NEPBRmszPCCq NG\BW5FFVVOR Mnzh[Y5p[W6lZYOgZZBweHSxc3nzJINwdWKrbnXkJJdqfGhiSV\OMe6y MU[yOVczPDh7OR?=
HLCZ01 MkfDSpVv[3Srb36gRZN{[Xl? MlTyOFDDqM7:TR?= M2XUNVI1KGh? M2TNXWROW09? MXfpcoNz\WG|ZYOgWHJCUUxiZYjwdoV{e2mxbjDjc41jcW6nZDD3bZRpKEmwdHXy[oVzd25vzsG= M1LielI2PzJ2OEm5
MGC803 NETlSmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4SyW|AuPjBizszN NVH0OHloPzJiaB?= MkPMTWM2OD12Nz6yOgKBkcLz4pEJOk41OyEQvF2= NHfLUHIzPTdyMUO3PC=>
SGC7901 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHnQVnIxNTZyIN88US=> NVfPNox7PzJiaB?= MnroTWM2OD12Mz61N-KBkcLz4pEJOU4yOiEQvF2= MVKyOVcxOTN5OB?=
MGC803 NEnGNZJHfW6ldHnvckBCe3OjeR?= NFTUcFE1OMLizszN M4rNVVgwOTZxMkSgbC=> NYHrcXpZfXC{ZXf1cIF1eyCFYnytZkBmgHC{ZYPzbY9v MXWyOVcxOTN5OB?=
SGC7901 MmrzSpVv[3Srb36gRZN{[Xl? NUPoOmJPPDEEoN88US=> M1njcVgwOTZxMkSgbC=> MnnpeZBz\We3bHH0d{BE[mxvYjDlfJBz\XO|aX;u NV3wWoFVOjV5MEGzO|g>
MCF-7  NWK4eVhvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYXNWIk3OS9zMDFOwG0> Ml3GO|IhcA>? NXG1[Zl[TE2VTx?= MmLx[Y5p[W6lZYOgZ4Ft[2m2cnnvcE1qdmS3Y3XkJINmdGxiZ4Lve5RpKGmwaHnibZRqd25? MVSyOVY3PzVzMB?=
MDA-MB-231  MoHWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV72dJhuOS9zMDFOwG0> NUjTbHFqPzJiaB?= MYnEUXNQ NF7qVYVmdmijbnPld{Bk[WylaYTybY9tNWmwZIXj[YQh[2WubDDndo94fGhiaX7obYJqfGmxbh?= NWj0eoRIOjV4Nke1NVA>
MDA-MB-231 M4e0c2Z2dmO2aX;uJGF{e2G7 M3f1U|AuPDBiwsXN NITxPFQ1NTJ2IHi= NV;LfplvcW6lcnXhd4V{KEORWD2yJJBzd3SnaX6g[ZhxemW|c3nvckBqdiCkb4ToJJRqdWViYX7kJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? NFOwXVgzPTV6N{OyPS=>
MCF-7 NHzVZ2dHfW6ldHnvckBCe3OjeR?= NID6W5YxNTRyINM1US=> M1v2OVQuOjRiaB?= M{nROYVvcGGwY3XzJJRp\SCnZn\lZ5R{KG:oIGTQRUBwdiCDQlPHNkBmgHC{ZYPzbY9vyqB? NE\GdlYzPTV6N{OyPS=>
MCF7-MX  NFPEZoFHfW6ldHnvckBCe3OjeR?= MXewMVQxKML3TR?= NGDEWFk1NTJ2IHi= Mmfr[Y5p[W6lZYOgeIhmKGWoZnXjeJMhd2ZiVGDBJI9vKEGEQ1eyJIV5eHKnc4Ppc47DqA>? Ml;VNlU2QDd|Mkm=
MDA-MB-231 NVm2RlBYTnWwY4Tpc44hSXO|YYm= MWOwMVQxKML3TR?= M3fTS|QuOjRiaB?= NIm3cWZ{fGmvdXzheIV{KHSqZTDlfJBz\XO|aX;uJI9nKEGEQ1eyJJVxKHSxIESuNlchfGmvZYOgeI8h[2:wdILvcEBt\X[nbDDifUAyOiCqwrC= NFfMOGQzPTV6N{OyPS=>
A2780 M{O3W2Z2dmO2aX;uJGF{e2G7 MVW1M|ExNzF3IN88US=> MXW0PEBp NY\WeZcy\GWlcnXhd4V{KEOxeD2yJIV5eHKnc4Ppc44hcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NUnNW2ZqOjV2MkS4PVg>
SKOV3  M1j3TWZ2dmO2aX;uJGF{e2G7 NXXmWZNHPS9zMD:xOUDPxE1? NULzPW1vPDhiaB?= NGD2WJBl\WO{ZXHz[ZMhS2:6LUKg[ZhxemW|c3nvckBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> M4Tkd|I2PDJ2OEm4
A2780 M3HrbGZ2dmO2aX;uJGF{e2G7 M{Lqe|UwOTBxMUWg{txO NXfEblhQPDhiaB?= NVH4NY5Q\WyndnH0[ZMhfGinIHX4dJJme3Orb36gc4YhTS2lYXTo[ZJqdiCjbnSgb4Vz[XSrbh?= M4XnfVI2PDJ2OEm4
SKOV3  NW[3N3NzTnWwY4Tpc44hSXO|YYm= MVW1M|ExNzF3IN88US=> M4rxRVQ5KGh? MVrlcIV3[XSnczD0bIUh\XiycnXzd4lwdiCxZjDFMYNi\GincnnuJIFv\CCtZYLheIlv MlLuNlU1OjR6OUi=
A2780 NFvlclFHfW6ldHnvckBCe3OjeR?= MlixOU8yOC9zNTFOwG0> NU\aXFBLPDhiaB?= MVjk[YNz\WG|ZYOgeIhmKGW6cILld5Nqd25ib3[gUk1k[WSqZYLpckBidmRiVnnt[Y51cW5? NGntNXczPTR{NEi5PC=>
SKOV3  MWjGeY5kfGmxbjDBd5NigQ>? MmDMOU8yOC9zNTFOwG0> MUm0PEBp NFHBbFZl\WO{ZXHz[ZMhfGinIHX4dJJme3Orb36gc4YhVi2lYXTo[ZJqdiCjbnSgWolu\W62aX6= MW[yOVQzPDh7OB?=
A2780 M3LJTGZ2dmO2aX;uJGF{e2G7 NX\hO4hTPS9zMD:xOUDPxE1? NE[2XnMyKGh? M1vEdolv[3KnYYPld{B1cGViZYjwdoV{e2mxbjDv[kBxNUGNVDDhcoQheC2HUlugbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= M3njblI2PDJ2OEm4
SKOV3  MYnGeY5kfGmxbjDBd5NigQ>? MUC1M|ExNzF3IN88US=> M2jDRlEhcA>? MkHObY5kemWjc3XzJJRp\SCneIDy[ZN{cW:wIH;mJJAuSUuWIHHu[EBxNUWUSzDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= M1raRVI2PDJ2OEm4
HCT-15 MlvaSpVv[3Srb36gRZN{[Xl? M2H6RlExNTVyIN88US=> NF:4b|I3NTN4IHi= NEfvd5NqdmS3Y3XzJJRp\SCneIDy[ZN{cW:wIH;mJGNQYC1{IHnuJIJwfGhiZH;z[UBidmRidHnt[UBl\XCnbnTlcpQhdWGwbnXy M1\ibFI2OjF6MEK4
HT-29  Mne2SpVv[3Srb36gRZN{[Xl? NHPoUWcyOC13MDFOwG0> NXvpVnNxPi1|NjDo NHniRpNqdmS3Y3XzJJRp\SCneIDy[ZN{cW:wIH;mJGNQYC1{IHnuJIJwfGhiZH;z[UBidmRidHnt[UBl\XCnbnTlcpQhdWGwbnXy MmO2NlUzOThyMki=
HSC3  NH:zTHVE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NIO3[IMx6oDVNECg{txO NGO1[2I1QCCq NH\DZ2ZKSzVyPUK1MlXDuTFwN{iwJO69VQ>? MUiyOVE6QDd6OR?=
HSC3  MkTVRZBweHSxc3nzJGF{e2G7 NVPoTHc5OjVizszN NIj0VXo1QCCq MmrvbY5lfWOnczDhdI9xfG:|aYO= NYn6VFUyOjVzOUi3PFk>
HSC3  NIP0fI5HfW6ldHnvckBCe3OjeR?= MViyOUDPxE1? MoD5OFghcA>? NYf3folU\XiqaXLpeJMhe2mpbnnmbYNidnSueTDy[YR2[2WmIH3p[5JifGmxbjDjc41jcW6nZDD3bZRpKEOHVB?= NIfROIYzPTF7OEe4PS=>
HSC3  NWjaXmxGTnWwY4Tpc44hSXO|YYm= MXWyOUDPxE1? NW\GRmdEPDhiaB?= MVvpcohq[mm2czDIV2M{KGOnbHygbY53[XOrb36gZ49u[mmwZXSge4l1cCCFRWS= NUHPO3FVOjVzOUi3PFk>
HSC3  MkPRSpVv[3Srb36gRZN{[Xl? MlvmNlUh|ryP Ml65O|IhcA>? NVH2ZXY3\GWlcnXhd4V{KE2PUD2yJIFv\CCPTWCtPUBxem:2ZXnud:Kh Mo\HNlUyQTh5OEm=
201T  MmO1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH\keGw4OiCq NH\XNHVFVVOR NF\zUIlKSzVyPUS4MlYhyrWP MlGzNlUxPTd7NEG=
273T MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX63NkBp M17rU2ROW09? NVT3XJlxUUN3ME24NE42KML3TR?= MXqyOVA2Pzl2MR?=
Hep-2 NE[wOI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYezNE82OC9zMECg{txO MonrNVIwOjRxM{[vOFghcA>? NGDXdXBFVVOR NYfMcYhIcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZo91cCC2aX3lJIFv\CCmb4PlJIRmeGWwZHXueEBu[W6wZYK= NVvESIxtOjR7OUi1OlQ>
Hep-2 MoLPRZBweHSxc3nzJGF{e2G7 MVi1NEDPxE1? NYfKN4p2OC12ODDo M2ftdWROW09? M3jtTolv\HWlZYOgZZBweHSxc3nzJIlvKGFidHnt[UBl\XCnbnTlcpQhdWGwbnXy NY\GeHZsOjR7OUi1OlQ>
Hep-2 NFXUV25HfW6ldHnvckBCe3OjeR?= NYm2WnVGPTBizszN M4TyRlAuPDhiaB?= MV\EUXNQ MlLpdoVlfWOnczD0bIUhfGWub33ldoF{\SCjY4Tpeol1gSCpcnHkeYFtdHl? MnezNlQ6QTh3NkS=
Hep-2 MWXGeY5kfGmxbjDBd5NigQ>? M1HES|UxKM7:TR?= NGjEOIwxNTR6IHi= MXTEUXNQ MlPW[IVkemWjc3XzJJRp\SCvUl7BJIV5eHKnc4Ppc44hd2ZiaGTFVnQ> NIXCT5UzPDl7OEW2OC=>
SGC-7901 M4nuTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmjkNVAwPTBxMUCwJO69VQ>? Ml[zNlQwPDhxN{KgbC=> M4XiRWROW09? NYnhNpdLcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZo91cCC2aX3lJIFv\CCmb4PlJIRmeGWwZHXueEBu[W6wZYK= MXqyOFk6Ojl3OB?=
MKN-45 M{ToSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3vMWVExNzVyL{GwNEDPxE1? MXmyOE81QC95MjDo M3rVNWROW09? M1PudolvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHLveIghfGmvZTDhcoQh\G:|ZTDk[ZBmdmSnboSgcYFvdmW{ MlP4NlQ6QTJ7NUi=
SGC-7901 M3fnc2Z2dmO2aX;uJGF{e2G7 NFi5fFgyOC93MD:xNFAh|ryP MnfiOFghcA>? MnK2SG1UVw>? MUnkc5dvemWpdXzheIV{KHSqZTDtVm5CKGW6cILld5Nqd25ibHX2[Yx{KG:oIFPPXE0zKGGwZDDQR25CKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz Ml3KNlQ6QTJ7NUi=
MKN-45 M4TqRWZ2dmO2aX;uJGF{e2G7 NVXNRZpYOTBxNUCvNVAxKM7:TR?= NX:zUoxDPDhiaB?= NFTWRYJFVVOR NIS5fpZld3ewcnXneYxifGW|IITo[UBuWk6DIHX4dJJme3Orb36gcIV3\Wy|IH;mJGNQYC1{IHHu[EBRS06DIHnuJIEh\G:|ZTDk[ZBmdmSnboSgcYFvdmW{ NULhR2R[OjR7OUK5OVg>
C666-1 MXHDfZRwfG:6aXPpeJkhSXO|YYm= NEjvSIUzOC16MDFOwG0> Mn;wNlQhcA>? M1mzWoRm[3KnYYPld{Bkd2yxbomg[o9zdWG2aX;uJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXyxsA> NX\Me2h7OjR6NUS4N|g>
CNE-1 MnfaR5l1d3SxeHnjbZR6KEG|c3H5 M3jXT|IxNThyIN88US=> NWXuZ2U4OjRiaB?= M16wWoRm[3KnYYPld{Bkd2yxbomg[o9zdWG2aX;uJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXyxsA> MkXXNlQ5PTR6M{i=
CNE-2 Ml;1R5l1d3SxeHnjbZR6KEG|c3H5 NVvGdHdPOjBvOECg{txO NH[0S48zPCCq M3;CfIRm[3KnYYPld{Bkd2yxbomg[o9zdWG2aX;uJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXyxsA> NEXmRngzPDh3NEizPC=>
C666-1 MmK4R5l1d3SxeHnjbZR6KEG|c3H5 MmTMOlAh|ryP NIiwR404KGR? M4L0UoVvcGGwY3XzJJJi\GmjdHnvckBkgXSxdH;4bYNqfHlidHjyc5VocCCFT2itNk1l\XCnbnTlcpQhdWGwbnXy MY[yOFg2PDh|OB?=
CNE-1 MnrPR5l1d3SxeHnjbZR6KEG|c3H5 M3nKVlYxKM7:TR?= M1fTWlch\A>? MYnlcohidmOnczDyZYRq[XSrb36gZ5l1d3SxeHnjbZR6KHSqcn;1[4ghS0:[LUKt[IVx\W6mZX70JI1idm6nch?= MYeyOFg2PDh|OB?=
SNU-1041 NYPWWoRtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoX5NE01OCEQvF2= MU[0PEBp MnLVbY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? M4XoXFI1Pjl{N{Cz
SNU-1041 NYW2SnZUTnWwY4Tpc44hSXO|YYm= MUWyNE8{OCEQvF2= Mm\ROEBp NELzfWVqdmS3Y3XzJIV5eHKnc4Ppc44hd2cEoFPIU3AtKEeUUEe4xsBidmUEoGjCVFHDqGG2IITo[UBTVkFibHX2[YzDqA>? MUCyOFY6OjdyMx?=
SNU-1041 M4[0O2Z2dmO2aX;uJGF{e2G7 MUSwMVQxKM7:TR?= MXW0JIg> M1vqW5VxNXKnZ4XsZZRmeyCFSF;QxsBi\nSncjD0doVifG2nboSge4l1cCCqaXfoJINwdmOnboTyZZRqd26| MVWyOFY6OjdyMx?=
SGC-7901 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2C2cFUxNTF{NTFOwG0> Ml\TNlQwPDhxN{KgbC=> M1\HO4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHLveIghfGmvZTDhcoQh\G:|ZTDk[ZBmdmSnboSgcYFvdmW{ Ml7BNlQ3PzZ|OUS=
SGC-7901 NH3MW4pCeG:ydH;zbZMhSXO|YYm= MmrINVAxKM7:TR?= Ml\PO|IhcA>? M175d4lv\HWlZYOgZZBweHSxc3nz NV7MWo9tOjR4N{[zPVQ>
SGC-7901 NUfjS|h5TnWwY4Tpc44hSXO|YYm= Mo\vO|UwOTByL{GyOUDPxE1? MWOyOE81QC95MjDo M33ZZ4lv[3KnYYPld{Bk[XOyYYPlMVgh[W6mID25JI1TVkFiZYjwdoV{e2mxbjDpckBjd3SqIITpcYUh[W6mIHTvd4UhdWGwbnXy MXyyOFY4PjN7NB?=
LMeC  M{\pPWZ2dmO2aX;uJGF{e2G7 NV\sOm9SOjBxNUCg{txO Mo\2OFghcA>? MXTk[YNz\WG|ZYOgeIhmKGW6cILld5Nqd25ib3[gR29ZNTJicILveIVqdg>? MYCyOFY2Pjd2Nh?=
CMeC-1 MmLER4VtdCCYaXHibYxqfHliQYPzZZk> MmjaNlAwPTBizszN MnrzOFghcA>? Mmq1bY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? NHHGOXMzPDZ3Nke0Oi=>
LMeC NVTLNVdIS2WubDDWbYFjcWyrdImgRZN{[Xl? NHXQbYQzOC93MDFOwG0> MYO0PEBp NV3uSmZscW6qaXLpeJMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlJIRmeGWwZHXueEBu[W6wZYK= MkLBNlQ3PTZ5NE[=
CMeC-1 NWrYNHhvTnWwY4Tpc44hSXO|YYm= MnXsNlAwPTBizszN MVy0PEBp MVjpcoR2[2W|IFexMXMh[XK{ZYP0 M3LSU|I1PjV4N{S2
LMeC NFnUfXFHfW6ldHnvckBCe3OjeR?= NIjkToUzOC93MDFOwG0> M4LwUFQ5KGh? MUPpcoR2[2W|IFexMXMh[XK{ZYP0 M{DaNFI1PjV4N{S2
CMeC-1 M1vZRWZ2dmO2aX;uJGF{e2G7 NV\0TYw5OjBxNUCg{txO M{jCUFQ5KGh? M3\ZRYRm[3KnYYPld{B1cGVibHX2[Yx{KG:oIHP5Z4xqdiCGMTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NWjjV5ZnOjR4NU[3OFY>
LMeC NXHYdGdQTnWwY4Tpc44hSXO|YYm= M3n3fVIxNzVyIN88US=> M1vlW|Q5KGh? M4HlNYRm[3KnYYPld{B1cGVibHX2[Yx{KG:oIHP5Z4xqdiCGMTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= MUiyOFY2Pjd2Nh?=
CMeC-1 NILI[4tHfW6ldHnvckBCe3OjeR?= NG\KVlgzOC93MDFOwG0> MnGyOFghcA>? NI\5WIxqdmS3Y3XzJINie3Cjc3WtN{Bi[3SrdnH0bY9v NF;BdWszPDZ3Nke0Oi=>
LMeC M3joVGZ2dmO2aX;uJGF{e2G7 NYXYS5VNOjBxNUCg{txO NXHNUVdEPDhiaB?= MkHjbY5lfWOnczDjZZNx[XOnLUOgZYN1cX[jdHnvci=> M362NFI1PjV4N{S2
OVCAR-3 M3PRSWNmdGxiVnnhZoltcXS7IFHzd4F6 NVj2TpJMOTBiwsXN M2PqRlEhcA>? MmXI[Y5p[W6lZYOgdIFkdGm2YYjlcE1qdmS3Y3XkJI93[XKrYX6gZ4Fv[2W{IHPlcIwh\GWjdHlCpC=> MnG4NlQ2OjB{Mke=
OVCAR-3 NYXEWJJsSXCxcITvd4l{KEG|c3H5 NF33T5EyOCEEtV2= M1HTPFEhcA>? MULwdo9ud3SnczDwZYNtcXSjeHXsMYlv\HWlZXSgZZBweHSxc3nzxsA> MVWyOFUzODJ{Nx?=
OVCAR-3 NHftTWNHfW6ldHnvckBCe3OjeR?= M1LQTFExKML3TR?= MV2xJIg> M37aN4VvcGGwY3XzJJBi[2yrdHH4[YwucW6mdXPl[EBi[3SrdnH0bY9vKG:oIHPhd5Bie2VvOdMg MYiyOFUzODJ{Nx?=
OVCAR-3 MkfQSpVv[3Srb36gRZN{[Xl? MVmxNEDDvU1? MWOxJIg> NIf0Todld3ewLYLl[5Vt[XSnczDOSk3PwkJiYXP0bZZifGmxbjDpcoR2[2WmIHL5JJBi[2yrdHH4[Yw> MXWyOFUzODJ{Nx?=
OVCAR-3 MVnGeY5kfGmxbjDBd5NigQ>? NU\nfmVLOTBiwsXN Mm\INUBp NYTseFJucW6qaXLpeJMheGGlbHn0ZZhmdC2rbnT1Z4VlKEGtdDDwbI9{eGixconsZZRqd25? M1zySFI1PTJyMkK3
CF33 Ml31SpVv[3Srb36gRZN{[Xl? MoL3NVAxKM7:TR?= MX:yOEBp M3HRc4lv\HWlZYOg[I94dnKnZ4XsZZRqd25ib3[gR29ZNTJicILveIVqdiCneIDy[ZN{cW:w NWjpWohoOjR3MEO3PFI>
CF33 NEO2PVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml7INVAuOTByIN88US=> MkX4NE01KGR? MkLDbY5pcWKrdIOgZ4VtdCCycn;sbYZmemG2aX;uJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NFTyelEzPDVyM{e4Ni=>
CF33 NIX0OYlHfW6ldHnvckBCe3OjeR?= NVjtR4dGOTBvMUCwJO69VQ>? MkXyOE0zPCCq MlfW[IVkemWjc3XzJINmdGy|IHnuJJRp\SCVIIDoZZNmKGGwZDDpcoNz\WG|ZYOgZ4VtdHNiaX6gS|AwTzFiYYLy[ZN1 MkfINlQ2ODN5OEK=
LNCaP NYXnN3dHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnfUNk82NzFyIN88US=> NXjHTZNbQTZiaB?= Mn[3bY5pcWKrdIOgZ4VtdCCpcn;3eIghe2mpbnnmbYNidnSueTDjc41jcW6nZDD3bZRpKGG2b4L2ZZN1[XSrbh?= M1HPfFI1Ojl4OUe4
LNCaP M{HmNWFxd3C2b4Ppd{BCe3OjeR?= MkHsNk82NzFyIN88US=> MlewPVYhcA>? MmHBbY5lfWOnczDhdI9xfG:|aYOgZ49u[mmwZXSge4l1cCCjdH;yeoF{fGG2aX6= NUjmS|JUOjR{OU[5O|g>
PC-3  M4fGXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlnBNE02OCEQvF2= NED5UGs1QOLCiXi= NVL5UYdRcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? NY\3XZd6OjRzMke4PFI>
PC-3  NXrEbWdqS2WubDDWbYFjcWyrdImgRZN{[Xl? M33ZUFAuOTByIN88US=> MYK3NkBp MYXk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? M37PZVI1OTJ5OEiy

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
Fibronectin / Vimentin / N-cadherin / E-cadherin ; 

PubMed: 28978083     


(A) Celecoxib treatment reduces the mesenchymal phenotype in SUM149 cells.

COX-2; 

PubMed: 29515134     


L02 cells exposed to PA (200 μM) with different concentrations of celecoxib (Cel, 5-40 μM) for 24 h. Celecoxib decreased protein expression of COX-2 compared with control as indicated by western blot. 

pAKT / AKT / PPARγ / PTEN ; 

PubMed: 24721996     


Immunoblots from N1-S1 cells treated with different dose celecoxib for 48 h. 

28978083 29515134 24721996
Immunofluorescence
PPARγ / PTEN ; 

PubMed: 24721996     


Immunofluorescence analysis in N1-S1 cells treated with 10 μM celecoxib for 48 h.

24721996
Growth inhibition assay
Cell viability; 

PubMed: 28521485     


Celecoxib caused the concentration-dependent inhibition of (A) GBC-SD and (B) NOZ cell growth. 

28521485
In vivo Celecoxib exhibits a potent, oral anti-inflammatory activity. Celecoxib reduces acute inflammation in the carrageenan edema assay and chronic inflammation in the adjuvant arthritis model with ED50 of 7.1 mg/kg and 0.37 mg/kg/day, respectively. In addition, Celecoxib also exhibits analgesic activity in the Hargreaves hyperalgesia model with ED50 of 34.5 mg/kg. Besides, Celecoxib produces no acute GI toxicity in rats at doses up to 200 mg/kg and no chronic GI toxicity in rats at doses up to 600 mg/kg/day over 10 days. [1] In a C3Hf/KamLaw female mouse model, Celecoxib increases median survival time of 105 days (range, 79-145 days) after 13.5 Gy local thoracic irradiation (LTI) alone to 142 days (range, 94-155 days). [3]

Protocol

Kinase Assay:[1]
+ Expand

COX enzyme assay in vitro:

Expression of COX protein in insect cells is determined by assessing PG-synthetic capability in homogenates from cells incubated for 3 days with COX-1 or COX-2 baculovirus. Cells expressing COX-1 or COX-2 are homogenized and incubated with arachidonic acid (10 μM). COX activity is determined by monitoring PG production. No COX activity is detected in mock-infected Sf9 cells. Celecoxib are preincubated with crude 1% CHAPS homogenates (2-10 μg of protein) for 10 minutes before addition of arachidonic acid. PGE2 formed is detected by ELISA after 10 minute incubation.
Cell Research:[2]
+ Expand
  • Cell lines: HNE1 and CNE1-LMP1
  • Concentrations: 0-75 μM
  • Incubation Time: 48 hours
  • Method: The antiproliferative effect of Celecoxib on NPC cells is assessed using an MTT assay. Cells are seeded into 96-well plates and allowed to attach for 24 hours. The cells are then treated with increasing concentrations of Celecoxib (0 to 75 μM) dissolved in DMSO (final concentration ≤0.1%) and incubated for up to 48 hours. After the incubation, 20 μL of MTT dye (5 mg/mL) are added to each well and cells are incubated at 37 °C for 4 hours. After removing the supernatants, the crystals are dissolved in DMSO and the absorbance is measured at 490 nm. The half-maximal inhibitory concentration (IC50) values and the 95% confidence intervals are calculated using probit regression using SPSS 15.0 software. The experiment is performed in triplicate and repeated at least three times.
    (Only for Reference)
Animal Research:[1]
+ Expand
  • Animal Models: A 0.1 mL aliquot of a 1% solution of carrageenan in 0.9% sterile saline or 1 mg of Mycobacterium butyricum in 50 μL of mineral oil is administered to the right hind foot pad of male Sprague−Dawley rats.
  • Formulation: Celecoxib is dissolved in 0.5% methyl cellulose and 0.025% Tween-20.
  • Dosages: ≤200 mg/kg
  • Administration: Administered via p.o.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 76 mg/mL (199.28 mM)
Ethanol 33 mg/mL (86.53 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+30% PEG 300+5% Tween 80+ddH2O
For best results, use promptly after mixing.
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 381.37
Formula

C17H14F3N3O2S

CAS No. 169590-42-5
Storage powder
in solvent
Synonyms SC 58635

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT03896113 Not yet recruiting Drug: Celecoxib 200mg capsule Endometrium Cancer Cliniques universitaires Saint-Luc- Université Catholique de Louvain June 30 2019 Phase 2
NCT03643744 Recruiting Drug: Celecoxib 200mg|Drug: Placebo Actinic Keratosis|Photodynamic Therapy Jeffrey B. Travers MD PhD|Wright State Physicians April 1 2019 Phase 1
NCT01344200 Not yet recruiting Drug: Celecoxib Pharmacokinetics of Celecoxib in Children Children''s Hospital of Eastern Ontario March 2019 Phase 4
NCT02876094 Recruiting Drug: celecoxib Spinal Muscular Atrophy (SMA) Hugh McMillan|Families of Spinal Muscular Atrophy|Gwendolyn Strong Foundation|Children''s Hospital of Eastern Ontario January 29 2019 Phase 2
NCT03672162 Recruiting Procedure: Total abdominal hysterectomy Total Abdominal Hysterectomy Pain Acute PostoperativeGabapentin Celecoxib Rajavithi Hospital September 1 2018 Not Applicable
NCT03541655 Active not recruiting Drug: Bupivacaine HCl|Drug: F14 (celecoxib) Total Knee Replacement|Postoperative Pain Arthritis Innovation Corporation May 4 2018 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I am doing an animal experiment with mice and planning to administrate S1261 via oral gavage. what are your recommendations for diluting the compound?

  • Answer:

    For oral administration, Celecoxib can be dissolved in vehicle one: "0.5% methyl cellulose and 0.025% Tween-20", or the vehicle 2 "2% DMSO/30% PEG 300/5% Tween 80/ ddH2O".

COX Signaling Pathway Map

COX Inhibitors with Unique Features

Related COX Products

Tags: buy Celecoxib | Celecoxib supplier | purchase Celecoxib | Celecoxib cost | Celecoxib manufacturer | order Celecoxib | Celecoxib distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID